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ABSTRACT
Europe is increasingly described as the region in the world with the least confidence in vaccination, and
particularly in the safety of vaccines. The aim of this systematic literature review was to gather and
summarise all peer-reviewed and grey literature published about determinants of Human Papillomavirus
(HPV) vaccine hesitancy in Europe. Ten thematic categories were identified across the 103 articles which
were included in the review. Participants from European studies most commonly reported issues with
the quantity and quality of information available about HPV vaccination; followed by concerns about
potential side effects of the vaccine; and mistrust of health authorities, healthcare workers, and new
vaccines. Comparative analyses indicated that confidence determinants differed by country and popula-
tion groups. This evidence supports the need to develop context-specific interventions to improve
confidence in HPV vaccination and design community engagement strategies aiming to build public
trust.
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Introduction
Human Papillomavirus (HPV) vaccination was introduced
into national immunisation programmes in all European
Union (EU) countries, apart from Poland, between 2006 and
2018.1
The HPV vaccine is mainly given to adolescent girls
(9–18 years old) to prevent cervical cancer and/or genital
warts, but sometimes also given to boys (e.g. Austria) or
men who have sex with men (e.g. the United Kingdom
(UK)) to prevent other HPV-induced cancers.1 Coverage
rates have been suboptimal in some EU countries, particu-
larly in Eastern Europe but also in Ireland, France, and
Denmark.2 Romania had initiated a programme in 2008,
but discontinued their HPV vaccination in 2014, due to
very low acceptance.1 These variations could partly be
explained by contextual and implementation factors
because the vaccine is currently delivered through schools
or public or private health systems, depending on the
country and immunisation programme. However, HPV
vaccination coverage rates are also affected by healthcare
worker (HCW) recommendations and public demand
which are both known to be influenced by confidence in
the vaccine.3
In recent years, HPV vaccination has suffered from growing
public distrust and criticism in Europe.4 Vaccine hesitancy has
been defined by the World Health Organization (WHO) SAGE
working group as a behaviour influenced by issues of confi-
dence, complacency, and convenience. Vaccine hesitancy does
not always imply vaccine refusal, as hesitant individuals can
accept certain vaccines but still have doubts about them.5
European vaccine hesitancy can partly be attributed to a lack
of confidence in vaccine safety, perceptions that vaccines do
not work, distrust of information, perceived low risks of vac-
cine-preventable diseases, as well as a lack of trust in HCWs,
authorities, and pharmaceutical companies.4,6
Many studies have been conducted in Europe and around the
world to explore public confidence in HPV vaccination. Some
reviews have tried to summarise these studies,7-10 but they have
generally focused on a particular population group or outcome.
The aim of this study was to systematically review all available
literature on determinants1 of HPV vaccine hesitancy for any
population group in Europe. The specific objectives of the review
were to understand determinants of HPV vaccine hesitancy in
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1In this paper, the expression “determinant” refers to “influences of vaccine acceptance”, as understood by the WHO Sage working group on vaccine
hesitancy, and does not always imply causation.
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the EU, compare determinants of HPV vaccine hesitancy in
different European Member States, and examine the importance
of safety concerns around HPV vaccination.
Methods
Search strategy and inclusion/exclusion criteria
A search strategy was developed in OVID Medline and adapted
for use across Embase, PsycINFO, Social Policy and Practice,
and Global Health in November 2016. Keywords were drawn
from the SAGE review on vaccine hesitancy5 and reviewed by
a panel of European experts, selected by the European Centre for
Disease Prevention and Control (ECDC) as reviewers for this
project. A grey literature search was simultaneously conducted
across Open Grey, Web of Science, PsycEXTRA, and organisa-
tion websites (ECDC, WHO, the UK Department for
International Development, and the Communication Initiative
Network).
The selection criteria, developed from the research question
by two researchers (EK, HL) and reviewed by the European
experts, were broad enough to ensure access to as many studies
as possible on determinants ofHPV vaccine hesitancy in Europe.
The search also focused on reasons for refusal or concern, public
trust and confidence, perceptions, attitudes, and beliefs about
HPV vaccination as the expression “vaccine hesitancy” was not
commonly used before the WHO SAGE Working Group on
Vaccine Hesitancy brought more attention to and usage of the
term, as well as characterising and defining it.11 Articles were
excluded when they did not include results about hesitancy,
confidence, or trust in HPV vaccination, for instance, articles
focusing solely on reasons for accepting HPV vaccination,
knowledge or awareness, or uptake or intentions to vaccinate
(without reasons). While certain socio-economic determinants
(i.e. age, income, education level) may be associated with HPV
vaccination uptake or intentions, they were excluded from this
study in order to retain focus on the less-studied, non-socio-
economic determinants such as mistrust and uncertainty.
Articles about all types of HPV vaccine were included.
No restrictions were made on study participants, settings, or
publication year. Articles from any EU or European Economic
Area (EEA) countries and language were included, although
only English language search terms were used. Articles compar-
ing different vaccines or countries from inside and outside
Europe were included only if data for HPV vaccination and/or
EU countries were included. Quantitative (observational cross-
sectional studies) and qualitative studies were included, but
articles without original data (i.e. commentaries or editorials)
or those which had the following foci were excluded: safety or
efficacy research, serologic or immunogenicity studies, pre-
clinical trials, cost-benefit or cost-effectiveness analysis.
Intervention studies without data about determinants of vaccine
hesitancy were also excluded as this review focused only on
determinants of vaccine hesitancy.
Selection, management, and analysis of articles
Articles were stored in Endnote X7 (Thomson Reuters) and
after duplicates were removed, were screened independently
by two (EK, CS) reviewers (title and abstract followed by full
text appraisal). Reviewers met to discuss differences in selec-
tion by reviewing reasons for exclusion or inclusion until
consensus was met. The number of articles included at var-
ious stages were summarised using the PRISMA chart. Data
from articles in English, Spanish, French, or Italian was
directly collected by EK and CS on a Microsoft Excel spread-
sheet while articles in other European languages were first
translated by experts at ECDC.
Methodologies for mixed-methods systematic literature
reviews – which combine the synthesis and analysis of quali-
tative and quantitative research – are relatively new and
developing rapidly.12 There is currently insufficient methodo-
logical evidence on how to conduct mixed-methods reviews to
identify and develop an understanding of health-related
beliefs and/or behaviours. The methods for this study were
therefore developed by combining and adapting methodolo-
gies from different types of mixed-methods reviews and are
described in more details in the paragraph below.12-19
Data extraction and analysis were performed by one
researcher (EK) and reviewed by two researchers (CJ, HL).
Two separate descriptive summaries and analyses of the stu-
dies were undertaken: one qualitative and one quantitative.
No integration of qualitative and quantitative studies was
performed. Data from mixed methods studies were included
in both analyses. Qualitative studies were analysed themati-
cally: a set of relevant themes was developed inductively, into
which each concern was categorised and analysed. No meta-
analysis could be performed for the quantitative studies, due
to the heterogeneity of the studies. Instead, a descriptive ana-
lysis was performed by reporting average proportions of par-
ticipants with specific concerns about HPV vaccination. Due
to some studies not presenting the raw data, each proportion
was calculated by averaging proportions extracted from the
studies. The quantitative studies identified through the sys-
tematic review were found to assess determinants of vaccine
hesitancy by looking at i) concerns among participants who
had refused (or would refuse) the HPV vaccine; ii) concerns
among participants who had accepted (or would accept) the
HPV vaccine; or iii) concerns among participants in general
(those do not correspond to the sum of the two first groups
but to studies that did not specify whether participants had
refused or accepted the HPV vaccine). These three categories,
summarised respectively as i) “hesitant” participants, ii) vac-
cine “favourable” participants and iii) “general” participants
were created by the reviewer (EK) to sort data extracted from
all studies, and to limit bias when reporting proportions based
on different denominators. It is important to note that con-
cerns or doubts were reported in all three groups, and hesitant
individuals can be found in hesitant, favourable and general
participants (see definition of hesitancy in the introduction).
Critical appraisal of studies was performed by one
researcher (CJ) and checked by another (EK). The “Effective
public health practice project quality assessment tool”20 was
used to appraise quantitative studies and the “Critical apprai-
sal skills programme qualitative checklist”21 was used for
qualitative studies. Mixed methods studies were appraised
using both of these tools. Studies were included regardless of
the outcome of their appraisal.
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Results
The systematic literature review yielded 3,143 unique peer-
reviewed and grey literature articles, of which 2,934 were
excluded after title and abstract review based on the inclusion
and exclusion criteria. From the 209 full text articles screened,
103 were included in the final analysis (see Figure 1).
Twenty out of the 31 qualitative studies were found to be of
“good” quality (vs. 6/31 “reasonable” and 5/31 “insufficient”); and
1/65 studies with quantitative data were assessed as “strong” (vs.
25/65 “moderate” and 39/65 “weak”) (see supplementary material
1). From themixedmethods studies, 0/7 were assessed as “strong”
for their quantitative sections (vs. 2/7 “moderate” and 5/7 “weak”),
while 2/7 were as assessed as “good” for their qualitative sections
(vs. 3/7 “reasonable” and 2/7 “insufficient”).
Most studies were conducted with parents (34/103, 10 of
which were with mothers only) and HCWs (22/103); and
reported results from the UK (28/103), Italy (12/103), France
(10/103), and Sweden (10/103). Readers should exert caution
when looking at the data, as studies included in the review were
conducted both before or after the introduction of the vaccine
(from 2005–2016), which could have influenced some public
opinions and therefore might not be representative of current
public perceptions in countries. The years in which study data
were collected are added in the results section wherever coun-
try-specific data is presented (if data collection year was not
available, the publication year is instead presented). More
information about study characteristics, including whether the
study was conducted before or after the vaccine was intro-
duced, are available in supplementary material 2.
Determinants of HPV vaccine hesitancy in Europe
Ten thematic categories of determinants of HPV vaccine
hesitancy in Europe were identified across the literature: i)
information issues, ii) concerns about vaccine safety, iii)
issues of trust, iv) effectiveness of the vaccine, v) influen-
cers, vi) issues related to sexual behaviour, vii) against all or
too many vaccines, viii) access barriers, ix) perceived need
for the vaccine and risk of disease, and x) fear of injections.
These are discussed in more detail in the following sub-
sections. The themes most frequently identified in qualita-
tive studies (Figure 2) were: concerns about potential side
effects of HPV vaccination (37 studies with qualitative
data), beliefs that information about the vaccine is insuffi-
cient and inadequate (31), and issues related to the sexual
health aspects of the vaccine (22). The categories of con-
cerns raised by the highest average proportions of hesitant
Articles identified through database 
searching 
(n = 5,671)
Additional articles identified through 
other sources (grey literature)
(n = 118)
Total articles screened
(n = 5,789)
Articles screened 
(n = 3,142)
Articles excluded 
(n = 2,934)
Full-text articles assessed for eligibility
(n =  208)
Articles excluded, with reasons (n= 105):
- 53: no data on HPV hesitancy
- 37: no original data
- 6: no data on HPV vaccination
- 6: data presented in wrong format
- 2: not translated in time (in German)
- 1: outside Europe (US)
Articles included in synthesis 
(n = 103)
Duplicates excluded 
(n = 2,647)
Figure 1. PRISMA flow diagram.
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participants across all quantitative studies in the review
(Figure 2) were: perceived insufficient and/or inadequate
information and knowledge about the vaccine (average of
44.2% of participants across all studies), fear of perceived
side effects (43.3%), mistrust of health authorities, any type
of doctor and new vaccines (39.7%), and doubts about the
effectiveness of the vaccine (33.7%). Fear of needles and
injections (9.4%) and low perceived need for the vaccine or
low risk of HPV/cervical cancer (14.1%) were the categories
least often reported by hesitant participants across all
studies.
Differences between countries (Figure 2) and population
groups (Figure 3) were identified, although care should be
taken when looking at these differences throughout the paper
as they could be due to differences in study design, variable
definitions, and participant selection. For instance, overall
results for a specific theme such as perceived lack of informa-
tion could reflect the views of a particular population if more
studies were conducted with this group. While perceived insuf-
ficient and inadequate information about HPV vaccination was
found to be the most important theme in studies with hesitant
participants in Romania, Denmark, Italy, Germany, and the
UK, fear about potential vaccine side effects predominated the
studies in the Netherlands, Greece, Hungary, and France. In
Spanish studies, the most commonly reported theme was doubt
about the effectiveness of the vaccine.
Concerns about potential side effects of HPV vaccination
were commonly reported by hesitant parents and HCWs in
studies but came second for studies with hesitant adolescents.
Adolescents included in studies mostly reported dissatisfaction
with the quality and quantity of information available about
HPV vaccination. This was the second most important issue
for hesitant parents included in studies. For studies with hesitant
HCWs, the second most commonly reported theme was a low
perceived need for the vaccine or a low perceived risk of HPV
and/or cervical cancer.
Information issues
Quantitative results
Insufficient knowledge or information, and beliefs that the infor-
mation available is unclear, biased and/or inadequate were iden-
tified in almost all articles reviewed. An average of 44% of
hesitant participants from quantitative studies reported that
there was insufficient information available about HPV vaccina-
tion, and/or that their own knowledge was insufficient,22-41
particularly in studies in Romania (2015, 81%),30 the
Netherlands (2009–2011, 67%),26,28 and Denmark (2010,
70%).35 This was also reported by 53% of general study
participants42-51 and 11% of favourable study participants.25
Additionally, 92% of hesitant parents in a study from 2009
from the Netherlands believed information about the vaccine
0%
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Figure 2. Average proportions of hesitant participants who reported certain categories of determinants of HPV vaccine hesitancy, by country.
Figure 3. Average proportions of hesitant participants who reported certain categories of determinants of HPV vaccine hesitancy, by population groups.
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was biased and unclear,26 while 32% of general parents in a study
from 2012 in Italy45 and 18% of general parents in a study from
2009 in the Netherlands44 believed information was unreliable.
General parents in studies in the UK (2005) and Italy (2007)
most frequently reported a need for more information about
HPV vaccination efficacy (74%),50,51 followed by vaccine safety
(48%),50 and duration of protection (10%).50
Qualitative results
In qualitative studies, a need for clearer, more transparent, and
unbiased information about HPV vaccination52-69 was identified
by some participants, together with the need for more verbal,
interactive communication.52,55,57,65,69 Additionally, some parti-
cipants recommended providing information in schools, for
instance by organising peer discussion groups with vaccinated
girls53,55-57,61,62,67,69; while others preferred social media or com-
munication methods that allow more discretion.52-54,62,69
Concerns about vaccine safety
Quantitative results
Concerns about the safety of HPV vaccination and potential
long- or short-term side effects were reported by an average of
43% of hesitant study participants.23-29,31,32,34-38,40,42,46,49,70-81
Fear of side effects was reported by an average of 52% of
general study participants51,82-97 and 17% of favourable study
participants.25,37,71 Concerns about side effects were particu-
larly prevalent among hesitant participants from studies in the
Netherlands (2009–2011, 69%),26,28 Romania (2010, 60%),79
and Greece (2005–2014, 54%).31,34,40,42,78
Qualitative results
Almost all qualitative articles described concerns about poten-
tial side effects of HPV vaccination,52-57,59,60,62,64,66,69,98-107
often described as fears of long-term side effects not yet
identified through trials.54,55,59,60,62,64,66,69,81,98-104,106 In quali-
tative studies, the most commonly reported perceived side
effect by parents was infertility.52,57,59,60,65,100,102,106 Other
perceived side effects included: autoimmune
complications,56,57,64,99,104,108 resistance of the virus to vac-
cines and/or treatment,99,102,105 cancer,52menstrual
complications,65 HPV infection,59 and death.65
In France, mothers and HCWs in studies conducted
between 2007–2010 discussed rumours about Hepatitis
B vaccination allegedly causing multiple sclerosis and some
expressed worries HPV vaccination could have similar side
effects.22,81,107,109 In Sweden, study participants in 2012 wor-
ried about the safety of HPV vaccination due to reports of
narcolepsy following H1N1 vaccination.56
Issues of trust
Quantitative results
Mistrust of health authorities was reported by an average of 47%
of general participants from studies in Sweden (2007),110
Hungary (2009),72 and the UK (2006)91 as well as 55% of hesitant
participants from studies in France (2015)74 and the Netherlands
(2009).26 Additionally, 12% of general practitioners (GPs) in
general in a study conducted between 2007–2010 in France
reported mistrust because of “excessive marketing” around
HPV vaccination.22
Mistrust of doctors was raised by 41% of hesitant parents
in a 2009 study from the Netherlands,26 and 45% of general
parents and young adults in studies from Hungary (2009)72
and the UK (2006).91
Mistrust of new vaccines and concerns about the relative
newness of the HPV vaccine was reported by an average of
36% of hesitant study participants.22,27,45,74,75,107,111,112 In
French studies, concerns about the newness of the vaccine,
reported by general GPs, decreased with time but remained
important: from 42% in 200722,107 to 37% in 201022 and 30%
in 2015.74 Mistrust of new vaccines was reported only by 9%
of general study participants in 2010 in Germany95 and 1% of
favourable study participants in Italy in 2013.111
Qualitative results
Beliefs that governments were not transparent,57,59 influenced by
vaccine manufacturers52,98 or were withholding information
about side effects65,98 were reported in some qualitative studies.
Some participants shared concerns about transparency,52,59 com-
mercial influences from pharmaceutical companies,52,98,104,113
and perceptions that doctors were dismissive and deliberately
withheld information about side effects.52,65,98,104 Mistrust of
pharmaceutical companies due to their underlying profit-
making motives and doubts about the trustworthiness of vaccine
trials and safety claims were also reported in studies in Bulgaria
(2009–2014),98,104 Romania (2010–2012),52 Sweden (2010,
2012),55,56 Ireland (2012),63 the Netherlands (2008),60 Spain
(2014),98 and the UK (2014).98
Finally, conspiracy theories about the vaccine allegedly
contributing to reducing world population or being an experi-
ment on young girls were reported in studies in Bulgaria
(2010–2013),104 Romania (2010–2012),52 Sweden (2014),57
the Netherlands (2015),65 and the UK (2007–2016).59,100,105
Effectiveness of the vaccine
Quantitative results
Across all studies, an average of 34% of hesitant participants were
found to doubt the effectiveness of the vaccine,23,24,26,32,34,37,73-
75,77,114 as well as 39% of general participants43,46,82,84-86,96 and
3% of favourable participants.26,37 Perceived low vaccine effec-
tiveness was particularly prevalent among hesitant participants
in studies in Spain (2013, 66%),112 the Netherlands (2009,
57%),26 and Italy (2006–2014, 37%).73,75,114 Additionally, 41%
of hesitant study participants74,112 and 31% of general study
participants84,86,97 doubted the length of protection of the
vaccine.
Qualitative results
In addition to worries about the duration of effectiveness of
the vaccine,22,52,55–57,60,64,67,99,104,105,108,109,115 participants in
qualitative studies also reported concerns that the vaccine
did not protect against all types of HPV.22,58,101,105,109,115,116
HUMAN VACCINES & IMMUNOTHERAPEUTICS 1619
Influencers
Quantitative results
While an average of 30% of hesitant parents reported not having
received any recommendation to vaccinate fromHCWs in studies
in Spain (2010–2011),36 Italy (2012–2015),29,45,75 Denmark
(2010)35 and France (2015),29 an average of 26% of hesitant
parents in studies from Spain (2010–2011)36 and Italy
(2012–2014)27,75 were advised not to vaccinate by their HCW.
Additionally, 19% of general adolescents in a study from
Germany in 2010 reported having been advised not to get the
HPV vaccine by their physician.95
Furthermore, an average of 47% of hesitant parents from
studies in Romania (2010)79 and Italy (2012)27,45 mentioned
they had received contradictory advice and opinions from
different healthcare professionals or specialists. A study pub-
lished in 2015 in Italy, where both boys and girls have been
vaccinated since 2017, showed 38% of general men who
attended sexual health clinics reported receiving contradictory
advice.87
Some adolescents also reported being influenced by their
parents, with 25% of hesitant adolescent girls from studies in
the UK (2008–2013),23,68 39% of general adolescent girls from
a study in Germany (2010)95 and 1% of general adolescent
girls from a study in Sweden (2008)47 mentioning they could
not get vaccinated because their parents had refused the
vaccine.25,70 Additionally, 11% of hesitant adolescent girls
from a 2015 study from Romania reported that their parents
thought the vaccine was unsafe.30
An average of 75% of hesitant parents from a 2010 study
from Romania79 and 39% of hesitant young women from
a 2013 study from Germany37 reported being influenced by
others who had refused HPV vaccination or who had recom-
mended against it. Additionally, 49% of general adolescent
girls from a 2007 study from the UK reported being influ-
enced by rumours.23
Qualitative results
Healthcare professionals, including school nurses and GPs, were
commonly referred to in qualitative studies as having the most
influence on HPV vaccination decisions.52,57,68,80,99,104,117
Additionally, the influence of family members, friends, and
parents of other children who did not vaccinate or who recom-
mended against the vaccine were reported across some
studies.52,57,67,100
Issues related to sexual behaviour
Quantitative results
The belief that HPV vaccination might encourage promiscuity
or earlier sexual debut in young girls was observed in an
average of 11% of hesitant study participants.22,23,26,32,50,71
This belief was also reported among 30% of general study
participants51,75,85,89,90,110,118 and 6% of favourable study
participants.22,71
An average of 20% of hesitant study
participants,22,26,27,50,74,75,107 20% of general study
participants,43,90,93,97,110 and 23% of favourable study
participants22 also believed that the vaccine would lead
to unsafe sexual behaviour and a decrease in the use of
condoms and cervical cancer screening. This fear was
reported by 19% of hesitant HCWs in studies in France
(2007–2015)22,74,107 and 23% of hesitant parents in studies
in Italy (2007–2014).27,50,75
Concerns about girls being too young were reported by an
average of 13% of hesitant study participants23,26,27,29,30,32,35,45,75
and 30% of general study participants.48,110 It was most com-
monly reported by hesitant parents in a study in the Netherlands
(2009, 52%)26 and hesitant school nurses in a study in Sweden
(2013, 48%).110 The concern that it is too difficult to discussHPV
vaccination with adolescent girls was also discussed in studies by
an average of 21% of hesitant parents and paediatricians,35,73 and
11% of general parents and HCWs.22,51,82,107,109 An average of
27% of general GPs in a 2014 study in France82 and 32% of
general adolescents in a 2008 study in Sweden47 also believed it
was difficult to talk about the vaccine with parents, while 21% of
general adolescents in a study in the UK (2007–2008) reported
embarrassment around getting a vaccine against a sexually trans-
mitted infection.85
Cultural and religious barriers to vaccination were indi-
cated by an average of 16% of hesitant participants,26,29,31,32
particularly in a study in the Netherlands (2009, 70%).26
Qualitative results
Qualitative studies reported beliefs that HPV vaccination might
encourage promiscuity or earlier sexual debut in young
girls61,65-67,100,101,106,108,119 and that the vaccine could lead to
unsafe sexual behaviour and a decrease in the use of condoms
and cervical cancer screening.55,57,63,64,66,67,80,106,108,109,119
Additionally, some participants mentioned that the vaccine
is being given to girls when they are too young because they
have not started to menstruate, are not yet sexually active or
married,54,57,58,61,100,108 or because they are too “naïve and
immature” to give their consent.98,103 Some also reported
that it is not easy to talk about HPV vaccination with girls
that are so young.20,53,54,59,61,63,79,98,99,105,108,114
Finally, cultural and religious influences on vaccine accep-
tance reported in studies included perceived low risk of infec-
tion because of certain lifestyles (being virgins when
marrying, having only one partner),54,57,60,61,65,99,100,105,108,109
and having a strong sense of fatality and/or belief that God
will protect girls.113
Against all or too many vaccines
Quantitative results
An average of 18% of hesitant study participants25,26,32,36,37,77,80
were against all vaccines in general. Additionally, 33% of general
study participants90,91 and 28% of hesitant study partici-
pants26,29,35,50,75,80 believed children already receive too
many vaccines, with 47% of hesitant parents in a 2015 study
in Germany29 and 46% of hesitant parents in studies in Italy
(2007–2015)29,50,75 raising this concern.
Qualitative results
A few qualitative studies reported that some participants were
against all vaccines.54,57,59,69,99,104
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Access barriers
Quantitative results
In quantitative studies, cost was raised as an issue by an average
of 32% of hesitant participants,31,38,74,75,80 particularly in studies
in Denmark (2009, 62%)80 and Greece (2008–2014, 54%),31 and
was also raised as a concern for an average of 47% of general
study participants in Germany, Greece, Hungary, Ireland, and
Sweden.46,47,94,97,120 The inconvenience of receiving multiple
doses was reported by 56% of general participants in studies in
Sweden (2007–2013),96,110 25% of hesitant participants in stu-
dies in France (2015)74 and the UK (2007–2008),71 and 10% of
favourable participants in a study in the UK (2007–2008).71
Increased workload created by administering the vaccine
was raised as a barrier by general school nurses in a study in
Sweden (2013, 40%),110 while general adolescents in studies in
Germany (2010, 12%)95 and Greece (2008–2014, 1%)31
reported being too busy to get vaccinated.
Other accessibility issues such as not having a consent
form, being absent from school when vaccination was being
administered, recent migration or not being in the target age
group were also reported by an average 10% of hesitant
participants in studies in the Netherlands (2009),26 the UK
(2011–2013),25,39 Italy (2008–2009),121 Denmark (2009),80
and Portugal (2007–2008).33
Qualitative results
The high cost of the HPV vaccine was mentioned in five
qualitative studies, from 2009–2010 in Sweden,64,102
2010–2014 in Bulgaria,98,104 2014 in the UK,98 2014 in
Spain,98 and 2012 in Ireland.63 Another access barrier was
the inconvenience of going to get multiple injections.67,115
The challenge of vaccinating in schools was discussed in
studies in Sweden (2010–2014)55-57 and in the UK
(2006–2015),59,61,101,116 with reasons including a lack of priv-
acy, children needing a calmer environment, missing classes,
and parental informed consent. The question of which health-
care professional should administer the vaccine was raised in
studies in Sweden (2010)55,64 and the UK (2007–2008),59 with
feelings of competition and distrust between gynaecologists
and paediatricians identified in a study in Greece (2016).99
Perceived need for the vaccine and risk of disease
Quantitative results
A perceived lack of need for the HPV vaccine was reported by an
average of 14% of hesitant study participants,25,31,32,36,38,70,75,121
5% of general study participants,88,95 and 2% of favourable study
participants.25
A perceived low risk of contracting HPV infection or
developing cervical cancer was reported by an average of
22% of hesitant study participants23,24,26,33,35,49,76,77,79,80,114
and 26% of favourable study participants.26 Among hesitant
participants, the perceived low risk of HPV was particularly
prevalent in studies in Italy (2007–2015, 44%)49,76,114 and the
Netherlands (2009, 38%).26
Qualitative results
Some participants in qualitative studies expressed
a perceived lack of need for the HPV vaccine due to
a perceived low risk of contracting HPV and/or cervical
cancer,55,59,66,80,100,109,115 a perceived low severity of the
disease,63,66,81 and/or the availability of alternative preven-
tion methods or abstinence.54,60,66,69,101,105,108,115
Fear of injections
Quantitative results
Fear of needles and injection pain was reported by 29% of
general study participants,47,85,89,92 9% of hesitant study
participants,24,25,30,31,37,39,46,72 and 5% of favourable study
participants.25
Qualitative results
Qualitative studies reported rumours among adolescents
about vaccination pain,102,116 the size of the needles and the
pain at injection increasing with each dose,62,116 the mistaken
belief of the vaccine being administered in the cervix,106,116
concerns about needle cleanliness,116 and the fear that the
injection could lead to a loss of virginity.68
Discussion
This systematic literature review identified 103 unique articles
on determinants of HPV vaccine hesitancy in Europe. Across
European studies, the most prevalent concerns were about:
insufficient and inadequate information about HPV vaccina-
tion; potential side effects of the vaccine; issues around trust
of health authorities, doctors, and new vaccines; and per-
ceived low vaccine effectiveness. While issues about the sexual
health aspects of the vaccine were reported in many qualita-
tive studies, they were less prevalent in quantitative studies,
which could be explained by the nature of qualitative studies
that ask open-ended questions.
Some differences were observed between studies from dif-
ferent European countries, with studies from Italy reporting
the highest average proportion of participants with concerns
about vaccination in general, issues related to the sexual
health aspects of the vaccine, and perceived low risk of
HPV/cervical cancer and consequent doubts about the need
for the HPV vaccine. Differences might be explained by
different contexts and national immunisation programmes
as well previous experiences with vaccination confidence
crises but could also be due to differences in study designs
and the methodology used for the systematic review.
Many concerns identified in this review were more fre-
quently observed among study participants in general rather
than in vaccine-hesitant participants, while some concerns
were also reported by large proportions of favourable partici-
pants. This could be an effect of the methodology used to
summarise proportions from different studies in this review:
the differences could be explained by the fact that proportions
from different years, countries, and population groups were
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averaged and compared. However, it could also point to other
issues. More research should therefore be conducted to
further explain these differences and explore perceptions
about HPV vaccination across the continuum of vaccine
hesitancy.
The most frequent concerns reported across studies and
among most study participants were a perceived lack of
information together with a fear of potential HPV vaccine
side effects. This confirms results from previous studies about
perceptions of vaccine safety being the most important deter-
minant of vaccine hesitancy for vaccines in general in
Europe.4,6 While some study participants raised specific con-
cerns about infertility, most reported having general safety
fears that they could not explain or specify. This could be
a consequence of the vaccine still being perceived as too new
and general uncertainty about the vaccine. A number of
studies have shown that uncertainty can influence as much
as empirical evidence in vaccination decision-making.122,123
Uncertainty is still often framed as something that can be
overcome by filling information gaps with more facts; how-
ever, mistrust of health authorities and some doctors was
commonly reported in this review, indicating that commu-
nication strategies need to include efforts to build and main-
tain public trust.124 Communication strategies should engage
communities, for instance by building alliances with civil
society or disease associations, organising school informa-
tion and discussion sessions with parents and peers, and
online discussion groups overseen and managed by local
health professionals. More research is needed to understand
information-seeking behaviours as well as how individuals
appraise and use information about HPV vaccination, and
finally to evaluate which communication and engagement
strategies are most effective with different population groups
(e.g. parents, teenagers, ethnic/religious minorities, or
HCWs).4,125,126 Evaluations should focus on communication
and engagement strategies developed by health authorities,
but also on information that the public is exposed to
every day, such as social media, online news, or television
documentaries.
While influences from family members, friends, other par-
ents or HCWs were commonly reported by parents in certain
studies, adolescents in those studies also reported rumours
circulating about HPV vaccination. The viral spread of nega-
tive rumours, particularly among adolescents through social
media, could prove to be an important challenge should
a confidence crisis arise. An example is the recent spread of
unverified and subsequently disproved concerns in Denmark
through YouTube videos and other social media that HPV
vaccine might cause Postural Tachycardia Syndrome (PoTS)
and Complex Regional Pain Syndrome (CRPS), as well as the
occurrence of mass-psychogenic illnesses that have been
observed and linked to HPV vaccination in Colombia and
Australia.127-129 These examples illustrate the rapidity by
which rumours can spread through social media and the
importance of influencers and group dynamics in HPV vacci-
nation confidence among adolescents as well as parents.
Faster research is therefore needed, such as through media
monitoring, to identify possible anxiety reactions, and to
inform time-sensitive strategies – including crisis
communication plans – on how to respond to them. The
confidence crisis that occurred in Denmark provides a good
example of how comprehensive strategies using
a combination of social and online media interventions,
engagement with mothers and adolescents, and risk commu-
nication strategies can successfully reinstate public trust in
vaccination. Denmark’s success in reversing the decreasing
vaccination coverage trend is in the process of being evaluated
and will constitute a good case study for other countries
facing similar issues.
HCWs, including GPs, paediatricians, and school nurses
were identified in many studies as strong influencers for
parents and adolescents but they were also found to have
concerns about the safety and effectiveness of HPV vaccina-
tion, which could prevent them from recommending the
vaccine.109,129 As HCWs are often considered the most trust-
worthy source of medical information,130 it is important to
address their own hesitancy, for instance by improving their
training on the introduction of new vaccines. Additionally, as
HCWs also reported facing difficulties talking about HPV
vaccination in some studies, it is important to provide more
support to HCWs and develop skills to manage difficult con-
versations. Some methods, such as motivational
interviewing131,132 have been employed outside of Europe
and could be adapted and evaluated in European countries.
Limitations
The results from this systematic literature review should be
interpreted with some caution. While the screening of articles
was conducted by two independent reviewers, data extraction
and critical analysis of studies could only be conducted by
a single reviewer. The results from the critical appraisal
showed that many quantitative studies were methodologically
weak, which can mainly be explained by the fact that the tool
used to assess quantitative studies was designed for interven-
tion studies while most studies in the field of vaccine hesi-
tancy are observational, and often cross-sectional. This
resulted in low scores for studies that did not use methods
such as blinding, which are not applicable to observational
studies. This limitation means that the results in this paper
could not be discussed together with the critical appraisal
results. While readers can refer to the results from the critical
appraisal in the supplementary materials, they should there-
fore interpret these with caution. Information about each
article’s reported conflicts of interests and funding sources
was also extracted and is available at readers’ request.
Additionally, two articles from Germany had to be omitted
due to translations not being finalised in time for this report,
which could have affected the findings for the country. The
database searches were also only performed in English, which
means some articles in other languages might have been
omitted.
The heterogeneity of the data and the analysis conducted
in the different studies, which did not allow for a meta-
analysis, might have introduced some bias in the quantitative
analysis. For instance, proportions of participants with speci-
fic concerns were compared across countries and population
groups, although the denominators (i.e. entire population,
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vaccine refusers, or vaccine acceptors) were sometimes very
different. This was partly managed by separating the analysis
for different groups. Averages were used to quantify different
concerns, although data from individual studies might have
been misrepresented especially as very high ranges of propor-
tions were observed. Finally, articles looking at socio-
economic determinants of vaccine hesitancy were excluded
as they were outside the scope of this review. Future reviews
should be conducted looking specifically at the impact of
those determinants on hesitancy.
Conclusion
Trust in HPV vaccination is currently being shaken in many
European countries, the impact of which is indicated by low
and/or decreasing coverage rates. Strategies developed with
the goal of addressing HPV vaccine hesitancy should not only
focus on providing more information about the safety and
effectiveness of the vaccine, but also aim to rebuild and
maintain trust in public health institutions, including HCWs
and health authorities, in order to prevent or manage future
potential confidence crises.
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